Investor Relations
News Release Details
Phio Pharmaceuticals Announces Upcoming Data Presentations at the ASGCT and ASCO Annual Meetings
Logo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Details are as follows: |
|
Event: |
24th Annual Meeting of the ASGCT |
Poster Title: |
INTASYL PH-762 Self-Delivering RNAi Targeting PD-1 Enhances the Therapeutic Efficacy of Systemically Administered HER2-Targeted CAR-T Cells in a SKOV3 Model of Human Ovarian Adenocarcinoma in NCG Mice |
Authors: |
|
Abstract Number: |
431 |
Date/Time: |
|
Event: |
The 2021 ASCO Annual Meeting |
Poster Title: |
INTASYL Self-Delivering RNAi Therapy Specifically Dual-Targeting BRD4 and PD-1 Elicits Complete Tumor Responses and Evidence of Synergy in a Subcutaneous Hepa1-6 Model of Murine Hepatoma in C57BL/6N Mice |
Authors: |
|
Abstract Number: |
e14537 |
Date: |
|
Archived versions of the Phio presentations will be made available on the "Investors – Events and Presentations" section of the Company's website (click here).
About Phio Pharmaceuticals Corp.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations and assumptions regarding the impact to our business and operations by the recent coronavirus outbreak, results from our preclinical and clinical activities, the development of our product candidates, the ability to obtain future financing, the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the
Contact
ir@phiopharma.com
Investor Contact
Ashley R. Robinson
arr@lifesciadvisors.com
View original content:http://www.prnewswire.com/news-releases/phio-pharmaceuticals-announces-upcoming-data-presentations-at-the-asgct-and-asco-annual-meetings-301279761.html
SOURCE